Nexpoint Asset Management’s AEON Biopharma AEON Stock Holding History

Nexpoint Asset Management’s Portfolio AEON Stock Details AEON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-553	Closed	-$400K	–	102
2022 Q4	$400K	Hold	553	–	–	0.03%	82
2022 Q3	$392K	Hold	553	–	–	0.03%	108
2022 Q2	$390K	Hold	553	–	–	0.03%	104
2022 Q1	$389K	Hold	553	–	–	0.05%	109
2021 Q4	$386K	Sell	553 -19	-3%	-$13.4K	0.05%	150
2021 Q3	$401K	Buy	+572	New	+$400K	0.07%	121

Other funds holding AEON

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

FTCM

Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return

ECP

Empyrean Capital Partners Los Angeles, California $3.07B AUM 34.24% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

SIM

Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return

CCA

Castle Creek Arbitrage Avon, Colorado $425M AUM 7.4% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

GCWM

Graham Capital Wealth Management Washington D.c., District of Columbia $113M AUM 11.26% 1-Year Est. Return

Nexpoint Asset Management's AEON Position: Q1 2023 in Review

Nexpoint Asset Management sold out of AEON Biopharma (AEON) in Q1 2023, closing a stake of 553 shares — an estimated $400K sold.

Nexpoint Asset Management first reported a position in AEON in Q3 2021 and held it in 6 quarters. The position peaked at $401K in Q3 2021. 21 funds tracked by Wall St. Rank hold AEON as of Q1 2023.

Nexpoint Asset Management reported no remaining AEON Biopharma position as of Q1 2023 after selling out during the quarter.
Nexpoint Asset Management sold 553 AEON Biopharma shares in Q1 2023, an estimated $400K.
Nexpoint Asset Management first reported a position in AEON Biopharma in Q3 2021 and held it in 6 quarters.
Nexpoint Asset Management's AEON Biopharma position peaked at $401K in Q3 2021.
21 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2023.

Based on Nexpoint Asset Management's 13F filing for Q1 2023, filed 15 May 2023.